Cannabidiol Reduces Intestinal Damage in Newborns with Severe Gut Inflammation

Greg Howard
28th June, 2024

Cannabidiol Reduces Intestinal Damage in Newborns with Severe Gut Inflammation

Cannabidiol treatment demonstrated a key protective effect against necrotizing enterocolitis by significantly reducing intestinal cell death (a), while macrophage populations were similarly depleted in both treated and untreated disease models compared to healthy controls (b).

Image adapted from: Soto et al. / CC BY (Source)

Key Findings

  • The study was conducted by researchers at Hospital Clínico San Carlos to explore the use of cannabidiol (CBD) as a treatment for necrotizing enterocolitis (NEC) in preterm infants
  • CBD significantly reduced inflammation and oxidative stress in the gut, leading to improved intestinal health and reduced severity of NEC
  • The study demonstrated that CBD treatment decreased mortality rates in the experimental NEC model
Necrotizing enterocolitis (NEC) is a severe and life-threatening inflammatory bowel disease that primarily affects premature infants. The disease has a high mortality rate and often leads to significant long-term health complications. Despite extensive research, the exact cause of NEC remains elusive, and effective prevention and treatment strategies are still lacking. However, a recent study conducted by researchers at Hospital Clínico San Carlos has introduced a promising new approach using cannabidiol (CBD) as a potential treatment for NEC[1]. NEC is a major concern for preterm infants due to their underdeveloped cardiac, respiratory, gastrointestinal, and immune systems. These vulnerabilities increase their risk of developing NEC, which can lead to severe intestinal damage, necessitating surgery in many cases and resulting in a high rate of mortality[2]. The financial burden of NEC is also substantial, with healthcare costs averaging over $300,000 per infant when surgical management is required[2]. The new study from Hospital Clínico San Carlos explores the use of CBD, a compound derived from the cannabis plant, known for its neuroprotective, anti-inflammatory, and antioxidant properties. CBD has already shown promise in treating neonatal cerebral hypoxic-ischemic pathologies, which are conditions caused by reduced blood flow and oxygen to the brain. The researchers developed an experimental model of NEC with an effectiveness rate of 73%, providing a robust platform to test the efficacy of CBD in treating this condition. Previous studies have highlighted various factors contributing to the onset and progression of NEC. For instance, the type of nutrition plays a significant role, with human milk (HM) being associated with a lower incidence of NEC compared to bovine milk-based formulas[2]. The exact mechanisms behind this protective effect of HM are not fully understood, but it is believed to involve a combination of nutritional and immunological factors[2]. Additionally, the role of bacterial colonization and the premature gut's increased reactivity to microbial ligands have been identified as key elements in the development of NEC[3]. The study from Hospital Clínico San Carlos builds on these findings by investigating how CBD can mitigate the inflammatory response and oxidative stress in the gut, which are critical factors in the pathogenesis of NEC. The researchers conducted a series of experiments using their NEC model to evaluate the impact of CBD on intestinal inflammation and damage. The results demonstrated that CBD significantly reduced the levels of inflammatory markers and oxidative stress in the gut, leading to improved intestinal health and reduced severity of NEC. This innovative approach aligns with other emerging strategies aimed at preventing and treating NEC. For example, the use of heparin-binding epidermal growth factor-like growth factor (HB-EGF) has shown promise in reducing the incidence of NEC[4]. Moreover, the implementation of standardized feeding regimens and increasing the availability of human milk have been effective in preventing NEC in neonatal intensive care units (NICUs)[4]. The introduction of CBD as a treatment option adds to this growing list of potential interventions, offering a novel mechanism of action that targets the inflammatory and oxidative pathways involved in NEC. In summary, the study conducted by Hospital Clínico San Carlos provides compelling evidence for the use of CBD as a treatment for NEC in preterm infants. By reducing inflammation and oxidative stress in the gut, CBD offers a new avenue for mitigating the devastating effects of this disease. This research not only expands our understanding of NEC but also opens the door to new therapeutic strategies that could significantly improve outcomes for affected infants.

MedicineHealthBiochem

References

Main Study

1) Cannabidiol decreases histological intestinal injury in a neonatal experimental model of necrotizing enterocolitis

Published 27th June, 2024

https://doi.org/10.1186/s42826-024-00211-9

Related Studies

2) Current Knowledge of Necrotizing Enterocolitis in Preterm Infants and the Impact of Different Types of Enteral Nutrition Products.

https://doi.org/10.3945/an.116.013193

3) Necrotizing enterocolitis: new insights into pathogenesis and mechanisms.

https://doi.org/10.1038/nrgastro.2016.119

4) Can we cut the incidence of necrotizing enterocolitis in half--today?

https://doi.org/10.3109/15513815.2010.483874


Related Articles

An unhandled error has occurred. Reload 🗙